Histone deacetylases: unique players in shaping the epigenetic histone code

Area of Science:

• Epigenetics
• Molecular Biology
• Cancer Research

Background:

• The epigenome, defined by DNA methylation and histone modifications, dictates gene expression.
• Histone acetylation/deacetylation by histone deacetylases (HDACs) maintains chromatin balance.
• Aberrant gene silencing, particularly of tumor suppressor genes (TSGs), is implicated in cancer development.

Purpose of the Study:

• To explore the therapeutic potential of targeting histone deacetylases (HDACs) in cancer.
• To investigate the role of HDACs in gene silencing and tumor suppressor gene inactivation.
• To highlight the development of HDAC inhibitors for cancer treatment and chemoprevention.

Main Methods:

• Classification of HDACs into three distinct classes (I, II, and III) based on homology to yeast proteins.
• Analysis of the relationship between histone modifications (acetylation, methylation) and gene expression states (silencing, activation).
• Review of current research on HDAC inhibitors in cancer chemotherapy and chemoprevention.

Main Results:

• Gene silencing is associated with deacetylated histones and specific DNA methylation patterns.
• Gene activation correlates with acetylated histones and distinct histone methylation marks.
• Several HDAC inhibitors are under development for cancer treatment, showing promise for chemoprevention.

Conclusions:

• Reactivating silenced tumor suppressor genes via HDAC inhibition presents a promising therapeutic strategy for cancer.
• Despite challenges like toxicity and specificity, ongoing research into HDAC structures and functions aims to develop targeted therapies.
• Targeted reactivation of specific genes affected in cancer holds significant potential for effective treatment and prevention.